Quick Hits

With the recent approvals of infliximab biosimilars, CT-P13 and SB2, and adalimumab biosimilar, ABP 501, by the U.S. FDA, the landscape of available anti-tumor necrosis factor (TNF) therapies for the treatment of inflammatory bowel disease (IBD) is changing right before our eyes. To understand the implications of this change, it is important to consider several […]

Debates

Most Crohn’s disease patients who undergo an intestinal resection will have postoperative recurrence. The most effective way to prevent recurrence is to initiate an anti-TNF within four weeks of surgery. It has been my practice that patients at high risk for postoperative Crohn’s disease recurrence initiate anti-TNF shortly after they are discharged from the hospital. […]

Debates

A surgical resection for a patient with Crohn’s disease is a major milestone in the natural history of their condition. It is without a doubt that patients who require surgery will make avoiding further surgery a priority and accordingly many patients will consider any possible preventive measure. I explain to patients that surgery is usually […]

Quick Hits

Vedolizumab (Entyvio, Takeda Pharmaceuticals America, Deerfield, IL) is a humanized monoclonal antibody to α-4 β-7 integrin, which is expressed on lymphocytes and is the ligand to mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1), preferentially expressed on endothelial cells in the gut vasculature. Vedolizumab selectively interferes with lymphocyte homing in the gut, thus affording the potential […]